基层医疗中可能改变 COVID-19 风险和严重程度的药物。

Drugs in primary care that may alter COVID-19 risk and severity.

机构信息

Brent Luu is an associate clinical professor at the University of California Davis's Betty Irene Moore School of Nursing in Sacramento, Calif. Sampath Wijesinghe is a clinical assistant professor in the PA program at Stanford (Calif.) University. Tarek Kassem is an assistant professor at California Northstate University in Elk Grove, Calif. Justin Lien is a student at Western University's College of Osteopathic Medicine in Pomona, Calif. Darrick Luu is a student at California Northstate University College of Health Science in Rancho Cordova, Calif. Rynee Wijesinghe is a student at California State University in Fresno, Calif. Leianna Luu is a student at the University of California Riverside. Gerald Kayingo is assistant dean, executive director, and professor in the Physician Assistant Leadership and Learning Academy at the University of Maryland Baltimore. The authors have disclosed no potential conflicts of interest, financial or otherwise.

出版信息

JAAPA. 2023 May 1;36(5):28-33. doi: 10.1097/01.JAA.0000918768.11544.e5.

DOI:10.1097/01.JAA.0000918768.11544.e5

PMID:37097779

Abstract

This article describes drugs used in primary care that could alter patients' risk for and severity of COVID-19. The risks and benefits of each drug class were differentiated according to the strength of evidence from 58 selected randomized controlled trials, systematic reviews, and meta-analyses. Most of the studies reported on drugs affecting the renin-angiotensin-aldosterone system. Other classes included opioids, acid suppressants, nonsteroidal anti-inflammatory drugs, corticosteroids, vitamins, biguanides, and statins. Current evidence has not fully differentiated drugs that may increase risk versus benefits in COVID-19 infection. Further studies are needed in this area.

摘要

本文描述了在初级保健中使用的可能改变 COVID-19 患者风险和严重程度的药物。根据从 58 项选定的随机对照试验、系统评价和荟萃分析中获得的证据强度，对每类药物的风险和益处进行了区分。大多数研究报告了影响肾素-血管紧张素-醛固酮系统的药物。其他类别包括阿片类药物、酸抑制剂、非甾体抗炎药、皮质类固醇、维生素、双胍类和他汀类药物。目前的证据尚未充分区分可能增加 COVID-19 感染风险与获益的药物。在这一领域需要进一步研究。